• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

    93.13 -1.06 (-1.13%)
    Streaming Delayed Price Updated: 10:38 AM EDT, Jul 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 128,062
    Open 94.84
    Bid (Size) 92.91 (100)
    Ask (Size) 93.32 (300)
    Prev. Close 94.19
    Today's Range 93.10 - 96.60
    52wk Range 28.66 - 97.63
    Shares Outstanding 115,926,629
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Corcept (CORT) Q2 Earnings: What To Expect
    Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect. Corcept mi... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Why Corcept (CORT) Stock Is Down Today
    What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to '... 
    Via StockStory

    Performance

    YTD
    +143.8%
    +143.8%
    1 Month
    +6.0%
    +6.0%
    3 Month
    +99.8%
    +99.8%
    6 Month
    +101.5%
    +101.5%
    1 Year
    +34.7%
    +34.7%

    More News

    Read More
    News headline image
    Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
    From Corcept Therapeutics Incorporated
    Via Business Wire
    Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup ↗
    Via Chartmill
    Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗
    Via Chartmill
    News headline image
    Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    3 Cash-Heavy Stocks with Questionable Fundamentals
    Via StockStory
    News headline image
    3 High-Flying Stocks We Steer Clear Of
    Via StockStory
    News headline image
    3 Unpopular Stocks We Steer Clear Of
    Via StockStory
    News headline image
    Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question
    Via StockStory
    News headline image
    Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
    From Corcept Therapeutics Incorporated
    Via Business Wire
    News headline image
    3 Reasons to Sell CORT and 1 Stock to Buy Instead
    Via StockStory
    News headline image
    3 High-Flying Stocks We Think Twice About
    Via StockStory
    News headline image
    Corcept (CORT) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Corcept (CORT) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Corcept (CORT) Q1 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Corcept (CORT) Q2 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures
    Via StockStory
    News headline image
    Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates
    Via StockStory

    Frequently Asked Questions

    Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
    Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
    What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
    Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
    The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
    What is the current price of Corcept Therapeutics Incorporated - Common Stock?
    The current price of Corcept Therapeutics Incorporated - Common Stock is 93.13
    When was Corcept Therapeutics Incorporated - Common Stock last traded?
    The last trade of Corcept Therapeutics Incorporated - Common Stock was at 07/29/26 10:38 AM ET
    What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
    The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 10.80B
    How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
    Corcept Therapeutics Incorporated - Common Stock has 11B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.